Differential impact of hormone receptor status on survival and recurrence for HER2 receptor-positive breast cancers treated with Trastuzumab

被引：0
作者：
Andrew McGuire
Olga Kalinina
Emma Holian
Catherine Curran
Carmel A. Malone
Ray McLaughlin
Aoife Lowery
James A. L. Brown
Michael J. Kerin
机构：
[1] National University of Ireland Galway,Discipline of Surgery, Lambe Institute for Translational Research, School of Medicine
[2] National University of Ireland Galway,School of Mathematics, Statistics and Applied Mathematics
来源：
Breast Cancer Research and Treatment | 2017年 / 164卷
关键词：
HER2; Trastuzumab; Luminal B; Luminal B HER2; HER2; HER2+(ER−); Breast cancer; Survival; Metastasis; Distant;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：221 / 229
页数：8
相关论文
共 34 条
  • [31] Johnston SR(2000)Inhibition of HER2/neu (erbB-2) and mitogen-activated protein kinases enhances tamoxifen action against HER2-overexpressing, tamoxifen-resistant breast cancer cells Cancer Res 60 5887-undefined
  • [32] Kurokawa H(2011)Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups J Clin Oncol 29 3351-undefined
  • [33] Untch M(2012)Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial Lancet Oncol 13 25-undefined
  • [34] Gianni L(undefined)undefined undefined undefined undefined-undefined
1234